Australian Diabetes Society position statement on Rosiglitazone (Avandia®)

The ADS has recently released a position statement on the use of rosiglitazone in the clinical management of patients with Type 2 diabetes. This position statement can be viewed at:

http://www.racp.edu.au/ads/rosiglitazone.pdf (PDF: 625 KB)

• Note: As at 15 December 2008 this position statement is under review by the Australian Diabetes Society:
  http://www.diabetessociety.com.au/position-statements.asp